Literature DB >> 34736959

Agonist-promoted kappa opioid receptor (KOR) phosphorylation has behavioral endpoint-dependent and sex-specific effects.

Peng Huang1, Chongguang Chen1, Danni Cao1, Melody Huang1, Lee-Yuan Liu-Chen2.   

Abstract

We reported previously that the selective agonist U50,488H promoted phosphorylation of the mouse kappa opioid receptor (mKOR) in vitro at four residues in the C-terminal domain. In this study, we generated a mutant mouse line in which all the four residues were mutated to Ala (K4A) to examine the in vivo functional significance of agonist-induced KOR phosphorylation. U50,488H promoted KOR phosphorylation in brains of the wildtype (WT), but not K4A, male and female mice. Autoradiography of [3H] 69,593 binding to KOR in brain sections showed that WT and K4A mice had similar KOR distribution and expression levels in brain regions without sex differences. In K4A mice, U50,488H inhibited compound 48/80-induced scratching and attenuated novelty-induced hyperlocomotion to similar extents as in WT mice without sex differences. Interestingly, repeated pretreatment with U50,488H (80 mg/kg, s.c.) resulted in profound tolerance to the anti-scratch effects of U50,488H (5 mg/kg, s.c.) in WT mice of both sexes and female K4A mice, while in male K4A mice tolerance was attenuated. Moreover, U50,488H (2 mg/kg) induced conditioned place aversion (CPA) in WT mice of both sexes and male K4A mice, but not in female K4A mice. In contrast, U50,488H (5 mg/kg) caused CPA in male, but not female, mice, regardless of genotype. Thus, agonist-promoted KOR phosphorylation plays important roles in U50,488H-induced tolerance and CPA in a sex-dependent manner, without affecting acute U50,488H-induced anti-pruritic and hypo-locomotor effects. These results are the first to demonstrate sex differences in the effects of GPCR phosphorylation on the GPCR-mediated behaviors.
Copyright © 2021. Published by Elsevier Ltd.

Entities:  

Keywords:  Aversion; Kappa opioid receptor; Phosphorylation; Sex differences; Tolerance

Mesh:

Substances:

Year:  2021        PMID: 34736959      PMCID: PMC9122667          DOI: 10.1016/j.neuropharm.2021.108860

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.273


  42 in total

1.  Comparison of pharmacological activities of buprenorphine and norbuprenorphine: norbuprenorphine is a potent opioid agonist.

Authors:  P Huang; G B Kehner; A Cowan; L Y Liu-Chen
Journal:  J Pharmacol Exp Ther       Date:  2001-05       Impact factor: 4.030

Review 2.  Fulfilling the Promise of "Biased" G Protein-Coupled Receptor Agonism.

Authors:  Louis M Luttrell; Stuart Maudsley; Laura M Bohn
Journal:  Mol Pharmacol       Date:  2015-07-01       Impact factor: 4.436

3.  Mutation of putative GRK phosphorylation sites in the cannabinoid receptor 1 (CB1R) confers resistance to cannabinoid tolerance and hypersensitivity to cannabinoids in mice.

Authors:  Daniel J Morgan; Brian J Davis; Chris S Kearn; David Marcus; Alex J Cook; Jim Wager-Miller; Alex Straiker; Michael H Myoga; Jeffrey Karduck; Emma Leishman; Laura J Sim-Selley; Traci A Czyzyk; Heather B Bradshaw; Dana E Selley; Ken Mackie
Journal:  J Neurosci       Date:  2014-04-09       Impact factor: 6.167

Review 4.  Targeting Itch with Ligands Selective for κ Opioid Receptors.

Authors:  Alan Cowan; George B Kehner; Saadet Inan
Journal:  Handb Exp Pharmacol       Date:  2015

5.  Sex difference in κ-opioid receptor (KOPR)-mediated behaviors, brain region KOPR level and KOPR-mediated guanosine 5'-O-(3-[35S]thiotriphosphate) binding in the guinea pig.

Authors:  Yu-Jun Wang; Khampaseuth Rasakham; Peng Huang; Darina Chudnovskaya; Alan Cowan; Lee-Yuan Liu-Chen
Journal:  J Pharmacol Exp Ther       Date:  2011-08-12       Impact factor: 4.030

6.  Evidence that the aversive effects of opioid antagonists and kappa-agonists are centrally mediated.

Authors:  R Bals-Kubik; A Herz; T S Shippenberg
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

7.  U-50,488: a selective and structurally novel non-Mu (kappa) opioid agonist.

Authors:  P F Vonvoigtlander; R A Lahti; J H Ludens
Journal:  J Pharmacol Exp Ther       Date:  1983-01       Impact factor: 4.030

8.  Effect of repeated administration of TRK-820, a kappa-opioid receptor agonist, on tolerance to its antinociceptive and sedative actions.

Authors:  Tomohiko Suzuki; Naoki Izumimoto; Yuko Takezawa; Morihiro Fujimura; Yuko Togashi; Hiroshi Nagase; Toshiaki Tanaka; Takashi Endoh
Journal:  Brain Res       Date:  2004-01-09       Impact factor: 3.252

9.  Determination of sites of U50,488H-promoted phosphorylation of the mouse κ opioid receptor (KOPR): disconnect between KOPR phosphorylation and internalization.

Authors:  Chongguang Chen; Yi-Ting Chiu; Wenman Wu; Peng Huang; Anika Mann; Stefan Schulz; Lee-Yuan Liu-Chen
Journal:  Biochem J       Date:  2015-12-03       Impact factor: 3.857

View more
  2 in total

1.  Agonist-Promoted Phosphorylation and Internalization of the Kappa Opioid Receptor in Mouse Brains: Lack of Connection With Conditioned Place Aversion.

Authors:  Chongguang Chen; Peng Huang; Kathryn Bland; Mengchu Li; Yan Zhang; Lee-Yuan Liu-Chen
Journal:  Front Pharmacol       Date:  2022-05-16       Impact factor: 5.988

Review 2.  An updated assessment of the translational promise of G-protein-biased kappa opioid receptor agonists to treat pain and other indications without debilitating adverse effects.

Authors:  Alexander R French; Richard M van Rijn
Journal:  Pharmacol Res       Date:  2022-01-29       Impact factor: 7.658

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.